Recent 8-K filings for CORT

• July 29, 2026, 4:07 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue up 32% to $256M; raises FY2026 guidance to $1.1-1.2B

  Revenue $256.1M (+32% YoY); net income $43.0M ($0.36 diluted EPS) vs $35.1M ($0.29) in Q2 2025.

• June 17, 2026, 4:36 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Corcept resubmits NDA for relacorilant to FDA for Cushing's syndrome; six-month review expected

  Resubmission based on pivotal GRACE trial and Phase III GRADIENT trial data.

• June 3, 2026, 8:00 AM ET litigation materiality 0.60 negative item 8.01

  DOJ declines to intervene in Corcept qui tam lawsuit; relator files amended complaint

  DOJ filed Notice of Election to Decline Intervention on May 19, 2026 in case U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics.

• April 30, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q1 revenue $164.9M (+5% YoY); raises 2026 guidance to $950-1050M; Lifyorli approved

  Revenue $164.9M, up 5% YoY from $157.2M. Net loss $31.8M vs net income $20.5M in Q1 2025 due to launch costs.

• March 25, 2026, 7:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer

  Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

• February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B

  Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).

• February 19, 2026, 6:59 PM ET litigation materiality 0.85 negative item 8.01item 9.01

  Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents

  Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.

• January 22, 2026, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction

  Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).

• December 31, 2025, 6:59 PM ET regulatory materiality 0.78 negative item 8.01item 9.01

  FDA issues Complete Response Letter for Corcept's relacorilant NDA in hypercortisolism

  FDA concluded benefit-risk assessment unfavorable without additional effectiveness evidence.

• November 4, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M

  Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.

• September 10, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  FDA accepts Corcept's NDA for relacorilant in platinum-resistant ovarian cancer; PDUFA July 11, 2026

  FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.

• July 31, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M

  Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.

• July 14, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer

  NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.

• May 5, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates

  Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.

• March 31, 2025, 7:59 PM ET other material materiality 0.95 positive item 8.01item 9.01

  Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly

  30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.

• March 3, 2025, 6:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  FDA accepts Corcept's NDA for relacorilant in Cushing's syndrome; PDUFA Dec 30, 2025

  FDA filed relacorilant NDA for endogenous hypercortisolism (Cushing's syndrome).

• February 26, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M

  Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).

• December 30, 2024, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Corcept submits NDA for relacorilant to treat Cushing's syndrome

  NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.

• October 30, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results

  Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.

• July 29, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M

  Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.

• May 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M

  Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.

• February 15, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases ×2

  Corcept Q4 revenue $135.4M (+31% YoY); reiterates FY2024 guidance $600-630M

  Q4 revenue $135.4M (+31% YoY); net income $31.4M ($0.28 diluted EPS) vs $16.6M in Q4 2022.

• January 8, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases ×3

  Corcept reports Q4 2023 revenue $135.4M (+31% YoY); guides 2024 rev $600-630M; announces $200M buyback

  Q4 2023 revenue $135.4M, up 31% YoY from $103.1M; full year $482.4M, up 20% from $401.9M.

• January 2, 2024, 6:59 PM ET litigation materiality 0.65 negative item 8.01item 9.01

  Court finds Teva does not infringe Corcept's Korlym patents; Corcept plans appeal

  District of New Jersey ruled Teva does not infringe Corcept's U.S. Patents 10,195,214 and 10,842,800.

• November 1, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q3 revenue $123.6M (+22% YoY); raises FY 2023 guidance to $470-$480M

  Revenue $123.6M (+22% YoY); net income $31.4M ($0.28 diluted EPS) vs $34.6M ($0.30) in Q3 2022.

• August 2, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q2 revenue $117.7M (+14% YoY); raises FY revenue guidance to $455-470M

  Revenue $117.7M, up 14% YoY; net income $27.5M ($0.25 diluted EPS) vs $27.4M ($0.24) in Q2 2022.

• May 3, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q1 revenue $105.7M (+13% YoY); raises FY2023 guidance to $435-455M

  Revenue $105.7M vs $93.7M Q1 2022; net income $15.9M ($0.14 diluted EPS) vs $22.8M ($0.20) YoY.

• February 28, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept reports Q4 revenue $103.1M, FY 2022 revenue $401.9M; guides 2023 revenue $430-450M

  Q4 2022 revenue $103.1M vs $98.8M Q4 2021; FY revenue $401.9M vs $366.0M.

• February 13, 2023, 6:59 PM ET litigation materiality 0.65 neutral item 8.01item 9.01

  Corcept reaches preliminary $14M settlement in securities class action; insurer to pay

  Settlement of Melucci v. Corcept case in Northern District of California.

• December 8, 2022, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Corcept settles patent litigation with Hikma; generic Korlym entry set for October 2034

  Settlement with Hikma resolves patent litigation over generic Korlym in District of New Jersey.

• November 3, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q3 revenue $101.7M (+5.8% YoY); tightens 2022 guidance to $400-410M

  Diluted EPS $0.30 vs $0.24 in Q3 2021; net income $34.6M.

• August 3, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue $103.4M (up 13% YoY); EPS $0.24; reiterates FY22 revenue guidance

  Revenue $103.4M (Q2 2021: $91.6M); diluted EPS $0.24 vs $0.21.

• May 5, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Corcept Q1 revenue $93.7M (+18% YoY); reiterates FY2022 guidance $400-430M

  Diluted EPS $0.20 vs $0.18 YoY; cash & investments $368.1M (up $32.3M in Q1).

• February 15, 2022, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  Corcept Q4 revenue $98.8M, net income $32.1M; guides 2022 rev $400-430M

  Q4 revenue $98.8M (+15% YoY); FY2021 revenue $366M (+3.4% from $353.9M).

• December 8, 2021, 6:59 PM ET other material materiality 0.75 negative item 8.01item 9.01

  Corcept wins patent appeal, discloses DOJ subpoena on Korlym sales, extends tender offer to Dec 15

  Federal Circuit affirmed PTAB decision upholding validity of '214 patent (expires 2037) against Teva challenge.

• November 3, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q3 revenue $96.1M (+11% YoY); narrows 2021 guide to $365-375M

  GAAP diluted EPS $0.24 vs $0.17 YoY; non-GAAP diluted EPS $0.30 vs $0.24.

• July 29, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Corcept Q2 revenue $91.6M; GAAP EPS $0.21; reiterates 2021 guidance $355-385M

  Revenue $91.6M (+3.4% YoY); GAAP diluted EPS $0.21 vs $0.23; non-GAAP EPS $0.30 vs $0.32.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.70 · Most common event earnings

27 positive 6 negative 16 neutral

source · CORT on sec.gov